Earnings Calls In Brief
This article was originally published in The Gray Sheet
J&J/Synthes deal on track
You may also be interested in...
And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market
The first company to enter the drug-eluting stent market will now be the first to depart.
New Products In Brief
J&J/Codman’s Orbit Galaxy
Abbott Expects To Resume Shipments Of Recalled MitraClip In Several Months
Abbott expects it will take several months to resume shipments of its MitraClip transcatheter mitral valve repair system following a voluntary global recall, but the firm says the recall is not likely to impact anticipated U.S. approval of the device later this year.